Strategic report Governance & remuneration Financial statements Investor information 35 Related party transactions GSK held a 12.4% interest in Aspen Pharmacare Holdings Limited at 31 December 2014 2013 12.4%.
Following the sale of half of the Groups holding in Aspen during March 2015, the investment is no longer accounted for as an associate.
At 31 December 2015, GSK owned 32 million shares or 27.8% of Theravance, Inc. now Innoviva Inc. which is a biopharmaceutical company listed on NASDAQ.
GSK began recognising Theravance as an associate on 1 September 2015.
The royalty revenues paid by GSK to Theravance in the period from 1 September 2015 to 31 December 2015 were 11 million 2014 nil.
At 31 December 2015, the balance payable by GSK to Theravance was 17 million.
At 31 December 2015, GSK held a 50% interest in Japan Vaccine Co. Ltd JVC through its subsidiary GlaxoSmithKline K. K. This joint venture with Daiichi Sankyo Co. Ltd is primarily responsible for the development and marketing of certain prophylactic vaccines in Japan.
During 2015, GSK sold 27 million 2014 27 million of its vaccine products into the joint venture.
At 31 December 2015, the trading balance due to GSK from JVC was 8 million and the balance payable by GSK to JVC was nil.
In addition, a loan of 6 million was made to JVC during the year and this amount remained due to GSK at 31 December 2015.
The aggregate compensation of the Directors and CET is given in Note 9, Employee Costs.
36 Adjustments reconciling profit after tax to operating cash ows 2015 2014 2013 m m m profit after tax 8,372 2,831 5,628 Tax on profits 2,154 137 1,019 Share of after tax profits of associates and joint ventures 14 30 43 Finance income net of finance expense 653 659 706 Depreciation 892 780 732 Amortisation of intangible assets 738 704 682 Impairment and assets written off 822 205 928 profit on sale of businesses 9,308 1,331 profit on sale of intangible assets 349 255 78 profit on sale of investments in associates 843 282 profit on sale of equity investments 342 149 36 Changes in working capital: Increase in inventories 111 529 95 Decrease in trade receivables 98 347 16 Increase decrease in other receivables 593 95 218 Increase in trade payables 40 91 125 Increase in other payables 2,141 698 393 Increase decrease in pension and other provisions 100 41 165 Share-based incentive plans 368 332 319 Fair value adjustments 313 12 Other 187 96 211 3,741 3,453 2,871 Cash generated from operations 4,631 6,284 8,499 GSK Annual Report 2015 183
